Division of Matrix Biology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
J Am Soc Nephrol. 2010 Nov;21(11):1819-34. doi: 10.1681/ASN.2010080793. Epub 2010 Sep 23.
The pathologic paradigm for renal progression is advancing tubulointerstitial fibrosis. Whereas mechanisms underlying fibrogenesis have grown in scope and understanding in recent decades, effective human treatment to directly halt or even reverse fibrosis remains elusive. Here, we examine key features mediating the molecular and cellular basis of tubulointerstitial fibrosis and highlight new insights that may lead to novel therapies. How to prevent chronic kidney disease from progressing to renal failure awaits even deeper biochemical understanding.
肾脏进展的病理模式是进行性肾小管间质纤维化。虽然近几十年来纤维化发生机制的研究范围和认识已经扩大，但有效的人类治疗方法直接阻止甚至逆转纤维化仍然难以捉摸。在这里，我们检查了介导肾小管间质纤维化的分子和细胞基础的关键特征，并强调了可能导致新疗法的新见解。如何防止慢性肾脏病进展为肾衰竭，还需要更深入的生化理解。
